QualityStocks Small-Cap and Micro-Cap Blogs: July 2021

Thursday, July 29, 2021

QualityStocksNewsBreaks –Splash Beverage Group Inc. (NYSE American: SBEV) CEO Featured in SmallCapVoice.com Interview

Splash Beverage (NYSE American: SBEV) chairman and CEO Robert Nistico was the featured guest in a recent SmallCapVoice.com interview. SmallCapVoice.com is a corporate investor relations firm recognized for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. During the interview with host Stuart Smith, Nistico talked about Splash Beverage’s business strategy as well as industry trends and metrics. Nistico noted that corporate success is often proportionate with qualified leadership, and Splash Beverage leadership includes a highly experienced management team, a strong board of directors, and a roster of professionals who have built invaluable industry relationships, as well as specialties in nutrition, marketing and other relevant spaces. Nistico presented an overview of his team, along with the company’s strategies for the first half of 2021 and operational goals set for the remainder of the year. “We have taken that well-known brand and re-energized it,” said Splash Beverage chair and CEO Robert Nistico during the interview. “That’s been a key acquisition for us, strategically. . . . Acquisitions are a big part of our ongoing strategy to build our portfolio but also to gain ground on revenue. . . . We’re just really hitting TapouT [brand] hard right now. You’ll start to see an acceleration of that product naturally, and throughout our Budweiser network. Really, spirits and wine, which really dominate our portfolio, will accelerate. And as I hinted before, acquisition is a large part of our overall growth strategy, so we’ll see what that subject has to offer to us in the near future.”

To view the full interview, visit https://ibn.fm/D3o3p

To view the full press release, visit https://ibn.fm/d8sAV

About Splash Beverage Group Inc.

Splash Beverage Groupspecializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the nonalcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique because it only develops and accelerates brands it perceives to have highly visible pre-existing brand awareness or pure category innovation. For more information about the company, please visit www.SplashBeverageGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) CEO Featured in M.A.D. Casters Interview

PlantX Life (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) was featured in a recent episode of the Make a Difference (“M.A.D.”) Casters podcast. M.A.D. Casters is a series that helps people learn ways in which they can find the passion to make a difference in their lives, whether financial, spiritual or personal and, in turn, make a difference in their communities and the world. PlantX CEO Julia Frank joined the broadcast, hosted by youth pastor and investor Bryan Saint-Louis, to share her amazing story and entrepreneurial journey — how she came from Germany, went to the Bahamas, worked for BMW, and then ended up leading PlantX Life. Frank also shared three of the most important lessons she learned along the way, the first of which is the importance of passion and following your gut. “You can only be successful at something you’re really, really passionate about. Obviously, it’s great when you have a job that can cover your bills, but, in the end, if you really want to have an impact and change something, you must do what you’re passionate about — whatever that might be,” Frank said. “So, follow, follow, follow your passion. Do what feels right for you. Follow your gut feeling. . . . Take the risk; don’t make yourself too comfortable. If it doesn’t work out, you can still change the direction.”

To view the full press release, visit https://ibn.fm/JDWTi

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.PlantX.com and the PlantX investor website at https://Investor.PlantX.com.

NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Completes Financial Filing Requirements, Upgraded by OTC Markets

InnerScope Hearing Technologies (OTC: INND), an emerging and disruptive leader in the direct-to-consumer hearing health technology space, has completed the filing of all required financial reports with OTC Markets and has submitted an attorney opinion letter, and has now been officially declared Pink Current. In order to receive that listing, the company filed all annual disclosure statements and the financial report for its first quarter ending March 31, 2021, with OTC Markets. According to the announcement, InnerScope is working to meet all requirements to upgrade to and trade on the OTCQB as soon as possible. “InnerScope is very pleased to announce today that we are again current with our financial reporting,” said InnerScope president and CEO Matthew Moore in the press release. “We appreciate the loyalty, patience and support from our shareholders during this period. Bringing the company Pink Current has been a key focus for our management team during the course of 2021. We also plan to upgrade our security to the OTCQB once we meet the independent director and other requirements and hope to announce this in the near term. Both of these steps are expected to increase shareholder value and, once these items are in our rearview mirror, allow us to continue focusing on driving market penetration and revenue expansion for InnerScope’s innovative and affordable direct-to-consumer hearing products.”

To view the full press release, visit https://ibn.fm/ZRyDh

About InnerScope Hearing Technologies Inc.

InnerScope is a manufacturer, distributor and retailer of direct-to-consumer (“DTC”) FDA-registered, Bluetooth app-controlled hearing aids, Bluetooth app-controlled personal sound amplifier products (“PSAPs”), hearing-related treatment therapies, doctor-formulated dietary hearing and tinnitus supplements, and assorted hearing and health-related products targeting the 48 million Americanssuffering from hearing-related issues. The company’s overall mission is to improve the quality of life for the estimated 70 million people in North America and the 1.5 billion people worldwidewho have some form of hearing loss. The management team of InnerScope is applying decades of industry experience and believes it is well positioned with its affordable Bluetooth app-controlled self-adjusting hearing technology and its innovative in-store sales and delivery system with its point-of-sale, free, self-check hearing screening kiosks to directly benefit when the Over-the-Counter (“OTC”) Hearing Aid Act becomes enacted, which is expected late 2021. The OTC Hearing Aid Law allows OTC hearing aids for perceived mild to moderate hearing losses to be sold in retail stores without users needing to see a professional or having a medical evaluation. The INND Hearing Kiosk is designed to enable the tens of millions of people with undetected or untreated mild to moderate hearing loss to treat themselves with the company’s easy, convenient and affordable OTC hearing aids in-store, off the shelf or online. For more information, please visit www.INND.com.

NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other health care providers in a live and hands-on setting. The Institute’s emphasis will focus on educating health care providers about OSA, Vivos’ treatments for OSA within their practice areas and providing training on Vivos’ related practice management tools for dentists. “Part of our mission is to spread the word about OSA among health care professionals who can help treat it. This new facility can accommodate 300 to 400 health care professionals a day, which not only significantly increases our clinical training capacity but also enables us to leverage the technology that we’ve built into the center to provide the highest-quality training for dentists all over the country and the world,” said Kirk Huntsman, Vivos chairman and CEO. “The Institute’s opening (which augments the online training we established over the last year and half) represents a critical milestone for us as we train independent dentists whose patients suffer from dentofacial malformations that may be associated with OSA and other debilitating health conditions. We are also proud that we are able to open our Vivos Institute as promised with the proceeds of our initial public offering that occurred just eight months ago.”

To view the full press release, visit https://ibn.fm/UpgPd

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – BAND Royalty Looking to Expand Royalty Library

BAND Royalty, an enterprising music technology company, has a music catalog offering over 50 songs that earn royalties for non-fungible token (“NFT”) holders every time they are played. “The catalog includes songs performed by famous artists such as Rihanna, Justin Timberlake, Cher, Beyonce, Jay-Z, and Jane Zhang. The artists are not directly affiliated with BAND Royalty, which simply owns the royalties for the songs, allowing for royalty revenue whenever a song is played, no matter the performer,” reads a recent article. BAND’s first series of NFTs is currently for sale beginning at 1 ETH and also features 17 unique art pieces. This series consists of eight different rarity levels for a total of only 3,000 NFTs. “The company intends to release up to 12,000 unique tokens across four series in the near future. All revenue from these upcoming series will be used to expand BAND’s royalty library.”

To view the full article, visit https://ibn.fm/tBhkU

About BAND Royalty

BAND Royalty lets music lovers and fans take their enjoyment of music to the next level by offering blockchain-secured BAND NFTs that enable holders to earn crypto from some of the world’s most popular songs. This unique opportunity allows individuals to share in income streams each time a song in the BAND music catalog is performed. The name BAND is derived from the initials of its co-founders, blockchain experts Barnaby Andersun (“BA”) + Noble Drakoln (“ND”). To learn more about the company, visit www.BANDRoyalty.com.

NOTE TO INVESTORS: The latest news and updates relating to BAND are available in the company’s newsroom at https://ibn.fm/BAND

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Emaginos Inc.’s Scalable Solution Designed to Produce Profoundly Better Results for Existing Funds

Emaginos, a REG-A public company (please see website if interested in investing) in the business of transforming K-12 public education, is guided by a business model projected to capture up to 40% of the total K-12 education market within the next decade based on company assumptions. “The first company with an actionable plan to transform and improve public schools rather than replace them, Emaginos will evoke this change without any additional funding, facilities or staff,” reads a recent article. The 2019 Gallup annual poll noted that only 51% of those surveyed were satisfied with the overall quality of education that students in kindergarten through grade 12 receive. Also, the satisfaction since 2005 has averaged 45%. There is clearly room for improvement. “Market demand is high for a scalable solution that will produce profoundly better results for existing funds invested,” the company says. “The United States government has identified effective education as one of the critical elements in addressing the current financial and unemployment crisis.”

To view the full article, visit https://ibn.fm/VsPOV

About Emaginos

Emaginos is working to improve the education system of the United States through a commitment to best practices. Opposed to replacing public schools with charter schools, Emaginos believes in restoring neighborhood schools and having them serve as focal points of their communities. Through the company’s model, one school in a district is transformed into a pilot. The pilot school incorporates the new model into the community and proves the concept. The lessons learned from this pilot school are then used to transition the model to the other schools in the district. For more information, visit the company’s website at www.Emaginos.com.

NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released results from its recent human clinical study focused on evaluating DehydraTECh(TM)-processed cannabidiol (“CBD”) for potential application against hypertension. The study, HYPER-H21-1, indicated a rapid, sustained drop in blood pressure with DehydraTECH-CBD as well as excellent tolerability. The partial results will be followed by more complete results after additional BP subset analyses and other data analyses are completed. According to the study’s lead investigator, Dr. Phil Ainslie, the early results appear to be extremely promising as blood pressure was reduced across both male and female volunteers and supported earlier findings that indicate DehydraTECH delivers superior performance over generic CBD controls. The results show potential for use in the at-risk hypertensive population and provide support for moving forward into more prolonged repeat dosing and longer-term clinical trials. The potential benefits these results show can be surmised by noting that other studies of coronary heart disease (“CHD”) report that lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, with heart failure also reduced by about 25%. “We are very encouraged by these early results in our 2021 hypertension program,” said Lexaris CEO Chris Bunka. “Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in stage 2 hypertensive volunteers.”

To view the full press release, visit https://ibn.fm/Tzj5p

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Why Accure Acne Inc. Is ‘One to Watch’

Accure Acne Inc., based in Boulder, Colorado, is a privately owned medical device company focused on developing an innovative and highly efficient solution to reducing and/or preventing the recurrence of acne vulgaris. “The company’s patented and patent-pending laser technology was designed to help improve acne sufferers’ long-term quality of life by offering a differentiated and impactful solution. . . . The company’s flagship product, the Accure Laser System, was granted CE Mark approval for the treatment of moderate inflammatory acne in 2020, which allows the company to commercialize its product in the European Union while working to develop an exclusive global IP portfolio,” reads a recent article. “The company’s pioneering technology has the potential to disrupt the vast global market of acne therapeutics. It is estimated that there are 40-50 million people affected by acne vulgaris in the United States each year, while roughly 85% of the global population will suffer from acne at some point, according to the company’s April 2021 investor presentation. In 2016, the acne vulgaris market was estimated at $2.6 billion in the U.S. alone.”

To view the full article, visit https://ibn.fm/wM9YH

About Accure Acne Inc.

Accure is committed to developing a novel and impactful solution for acne sufferers that employs a revolutionary technology designed to improve their long-term quality of life. The company, with a uniquely impressive clinical and technical team, is focused on developing a truly differentiated and protected product for clinicians worldwide. The Accure device has been granted CE Mark approval, which allows Accure to commercialize in the European Union while creating a global and exclusive intellectual property portfolio. The company is committed to developing a uniquely compelling value proposition. Accure has developed a clear and compelling go-to-market strategy, leveraging significant commercialization experience and regulatory expertise. For more information about the company, visit www.AccureAcne.com.

NOTE TO INVESTORS: The latest news and updates relating to Accure Acne are available in the company’s newsroom at https://ibn.fm/ACNE

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Sustainable Green Team Ltd. (SGTM) Is an Industry Powerhouse

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, is maximizing profit through its synergistic business model that incorporates its subsidiaries. The model enables it to receive mulch feedstock of high quality at a much lower net cost for maximum profit. “SGTM broke records in 2020 with year-over-year increases of 764% in revenue and 4,817% in gross profit, and the trend continued for Q1-2021 with quarter-over-quarter increases of 16.7% in revenue and 8.6% in gross profit,” a recent article reads. “The company’s business model — unique to the industry — allows it to profit in two ways: first by offering paid services that enable it to acquire its feedstock and second by processing and selling the transformed product to large-scale commercial retailers such as The Kroger Co., Circle K, Menards Inc. & Old Castle Lawn & Garden. ‘This business combination has created an industry powerhouse, and with our combined strengths put us in an ideal position to increase our sales and resulting margins as our combined operations benefit from the resulting vertical integration and economies of scale,’ said Mulch Manufacturing CEO Ralph Spencer.”

To view the full article, visit https://ibn.fm/iIASh

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging, and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit https://ibn.fm/ZdiFf.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – reAlpha CEO Authors Forbes Article Discussing Tech’s Disruption in the Real Estate Space

reAlpha CEO Giri Devanur recently wrote an article titled “Seven Ways Technology Is Disrupting Real Estate.” In the article, Devanur, a member of the Forbes Business Council, noted that buying a home today looks different from how previous generations purchased their homes. The internet has created a resource that most people turn to first, with COVID-19 aiding the adoption of technology. Devanur outlined seven ways that technology has impacted the real estate sector: data, contracts, showings, fintech, online investment, smart home technology, and new rental avenues.

“The traditional real estate model was always the same: buy the property and rent it out,” Devanur wrote in the article. “The internet has brought about new ways of generating revenue. Airbnb wasn’t first in the short-term rental space, but it certainly dominates it now. The global short-term rental market is estimated at $87 billion. Especially with COVID-19 restrictions being lifted, that market needs servicing. A lot of servicing. Airbnb CEO Brian Chesky told CNBC his platform will need millions of more hosts in the coming months to meet the demand. I predict virtual showings and online closings will not fade with the pandemic. Instead, expect technology to keep changing the industry. Blockchain technology is one area that has the potential to have massive impacts on real estate. Cryptocurrencies are, at times, already being accepted as payment for homes that could expand in the future. Blockchain also has the potential to be utilized for documentation software because of its inherent security features. Technology is shaping real estate’s future, so be sure to stay ahead of the curve.”

To view the full article, visit https://ibn.fm/dK6DB

About reAlpha

reAlpha is using technology to bring the power of real estate investing to the 99%. reAlpha merges the most historic asset with the technology and business model of the future: Airbnb. The reAlpha platform provides meaningful wealth generation opportunities for everyone: short-term passive income through Airbnb as well as equity-driven capital appreciation. However, they also believe that real estate investing is deeper than just financial returns, it is the pride of ownership and the freedom of financial security. They are driven every day to create not only lucrative returns for their members but also to deliver exceptional experiences and positively impact the communities in which reAlpha lives and operates. To learn more visit realpha.com.

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Hero Technologies Inc. (HENC) Eyes Strategic Business Plan Toward Vertical Integration

Hero Technologies (OTC: HENC), a cannabis company working toward vertical integration, is focused on a strategic business plan. This includes everything from genetic engineering of cannabis, cannabis cultivation space, and production and distribution licenses to consumer packaging, as well as retail and dispensary operations. “HENC’s growing portfolio includes a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants,” notes a recent article. “Hero Technologies is also planning expansion in cultivation and dispensary operations into both Colorado, through its wholly owned subsidiary Mile High Green LLC, and Massachusetts, through wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com.”

To view the full article, visit https://ibn.fm/lm1Zg

About Hero Technologies Inc.

Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. Hero Technologies’ strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information about the company, visit www.HeroTechnologiesinc.com.

NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Begins Trading on NASDAQ under KAVL Ticker

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi(R) Vapor LLC, began trading its common stock on the Nasdaq Capital Market at market open today, July 29, 2021. The company is trading under the ticker symbol KAVL. In the announcement, the company acknowledged key players that had provided support for the company as it made this transition; those key players include BTIG, Maxim, and Ladenburg Thalmann & Co. Kaival Brands works with Bidi Vapor to provide recreational, noncombusted alternatives for adult cigarette smokers while strongly opposing all illegal underage tobacco use by minors. The company is committed to preventing youth use of electronic nicotine delivery systems (“ENDS”) through responsible marketing to adult tobacco users as well as working with law-abiding retailers and distributors, and complying with all federal and state laws and taxes applicable to the distribution of Bidi products. “We are excited to be listed on the Nasdaq,” said Kaival Brands chief operating officer Eric Mosser in the press release. “Our company is built upon strong core values, and we believe Nasdaq is the right exchange to serve us and our shareholders.”

To view the full press release, visit https://ibn.fm/2TjZH

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) Featured in Stock2Me Podcast, Secures $0.5M in Follow-On Orders

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art components and semiconductor chips for satellite and 5G communications networks, defense, space, and other commercial applications, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. AMPG’s Director of Communications Shan Sawant joined the latest episode to discuss AmpliTech’s business model and offer an overview of the company’s proven, decades-long track record of providing vital radio frequency components to an impressive list of clients. “AmpliTech provides high-quality radio frequency (‘RF’) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.”

In addition, AmpliTech today announced its receipt of $0.5M in orders for custom low noise amplifiers (“LNAs”) for a global high-speed satellite broadband services provider. Per the update, the amplifiers, which are expected to ship in the third quarter, will be utilized in satellite ground stations to disseminate valuable geosynchronous equatorial orbit (“GEO”), low earth orbit (“LEO”) and medium earth orbit (“MEO”) satellite system data to end users. “We have years of experience working with this customer to deploy customized low noise amplifiers in their satellite systems,” said AMPG CEO Fawad Maqbool. “It recognizes the value of our industry leading performance and reliability to deliver data and communications that are unimpacted by environmental interference. We are excited to build on this relationship to maximize the efficiency of the customer’s communications systems and look forward to working with the customer in the future.”

To view the full press releases, visit https://ibn.fm/qsNXJ and https://ibn.fm/CXiXp

About AmpliTech Group Inc.

AmpliTech Group designs, develops and manufactures state-of-the-art radio frequency (“RF”) components for global satellite communications, telecom (5G & IoT), space, defense, and quantum computing markets as well as provides systems and component design consulting services. AmpliTech has a 13+ year track record of developing high performance, custom solutions to meet the unique needs of some of the largest companies in the global industries it serves. The company is proud of the unique skills, experience and dedication of its focused team, which enables AmpliTech to deliver superior solutions, faster time to market, competitive pricing and excellent customer satisfaction and repeat business. For more information about the company, visit www.AmpliTechinc.com.

NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Enters Strategic Alliance Focused on Recovery of Isotopes Needed for Emerging Cancer Therapeutics

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, is partnering with RadTran LLC to evaluate the recovery of thorium, and potentially radium, from UUUU’s existing rare earth carbonate and uranium process streams for use in producing medical isotopes for emerging targeted alpha therapy (“TAT”) cancer therapeutics. The partnership is outlined in a strategic alliance agreement and has the potential to develop commercial technologies and sources of isotopes needed for a new domestic medical supply chain. RadTran is a Colorado-based tech-development company working on closing critical gaps in the procurement of medical isotopes for various applications. “At its heart, the Energy Fuels’ Alliance with RadTran is about maximizing the value and human benefit of our existing uranium and rare earth feeds at the White Mesa Mill,” said Energy Fuels president and CEO Mark S. Chalmers in the press release. “Energy Fuels has a long track record of ethically and responsibly processing a wide variety of naturally occurring radioactive materials at the White Mesa Mill for the recovery of uranium and, more recently, rare earths. In our view, recovering medical isotopes from these same streams that would otherwise be lost to direct disposal is a great way to maximally use all of our feeds. Indeed, we are essentially replicating China’s monazite plan. China purchases monazite from around the globe, recovers the uranium for use in their nuclear industry, recovers the thorium presumably for use in their nuclear and pharmaceutical industries, and recovers the rare earths for processing into advanced materials needed for various clean energy and advanced technologies. Our White Mesa Mill is a facility unique to the United States that has the potential to do the same thing at world standards. . . . We believe Energy Fuels has the potential to create a domestic supply of thorium and possibly radium that can be harvested using RadTran’s technologies for use in the production of the next generation of cancer therapies, a potentially multibillion dollar industry.”

To view the full press release, visit https://ibn.fm/JQKff

About Energy Fuels Inc.

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 (“U3O8”)to major nuclear utilities. Energy Fuels also produces vanadium from certain of its projects, as market conditions warrant, and is ramping up to commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of more than 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant as well as REE carbonate from various uranium-bearing ores. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101-compliant uranium resource portfolios in the United States and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces LOI, Enters Promising Australian Medical Cannabis and OTC CBD Space

Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, as signed a Letter of Intent (“LOI”) with Evergreen Pharmacare Pty Ltd. Evergreen is a licensed importer and distributor of medical cannabis products based in Australia, and the LOI calls for Flora to provide raw and finished medical cannabis products for medical cannabis patients. Flora plans to ship the medical-grade cannabis products after the company obtains the correct export licenses and completes its first commercial harvest. The LOI is the second that Flora has signed since recent changes in Colombian law allow the company to sell and export raw cannabis materials, namely dried flower, in addition to derivatives. According to the company, the Australian medical cannabis market is forecast to surpass AU$200 million in 2021 and US$1.5 billion by 2025; some experts forecast that the pharmacist-only CBD market in Australia will reach AU$250 million with approximately 2 million consumers. A key factor in this growth is the decision by the Australian government to move cannabidiol (“CBD”) from Schedule 4 to Schedule 3, which makes it permissible to sell and buy CBD products over the counter. “The agreement with Evergreen will allow us to establish a local partner in Australia while generating incremental revenue from our Colombian cannabis facility and as legislation evolves within Australia,” said Flora Growth chief revenue officer Jason Warnock in the press release. “This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market. Down-scheduling CBD fits well with Flora’s long-term consumer product strategy of providing proven cannabinoid wellness and beauty products to consumers around the world and we are excited to work with our partners on this new opportunity.”

To view the full press releases, visit https://ibn.fm/5ACI5

About Flora Growth Corp.

Flora Growth is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Featured in SmallCapVoice.com Interview

Friendable (OTC: FDBL), a mobile technology and marketing company, was featured in a new interview with SmallCapVoice.com Inc. (“SCV”). Friendable CEO Robert A. Rositano Jr. joined SCV’s Stuart Smith to discuss the timely launch of the company’s version 2.0 of the Fan Pass livestream artist platform and its aggressive strategy to achieve “immense scalability.” Rositano Jr. explains that the Fan Pass app is a platform and true artist partner that enables authentic interaction between artists and their fans. The app’s features are tailored to both the artist and the fan, catering to individual needs and wants, including a suite of products and services enabling artists to generate revenue from virtual performances, subscribing fans, merchandise sales and other opportunities. Fans have the ability to follow specific artists and genres they love, while artists can provide their most loyal supporters with behind-the-scenes access.

To view the full press release, visit https://ibn.fm/PLjC8

About Friendable Inc.

Friendable is a mobile technology and marketing company focused on developing and identifying products, services and brand opportunities with mass market potential and scalability. Friendable published its first mobile application in the Apple App Stores and Google Play stores in 2014, in the social networking and dating category. The Friendable app achieved over 1.5 million downloads, Top 10 worldwide rankings, and has led to celebrity-related marketing opportunities and various relationships with well-known music artists, as well as up-and-coming independent artists. Friendable has since removed the social dating app from the app stores and has pivoted its business focus to Fan Pass, the livestream artist platform. Launched July 24, 2020, the Fan Pass livestream platform has proven to be invaluable for artists and fans alike as performances shifted from the stage to the screen. Friendable was founded by brothers Robert A. Rositano Jr. and Dean Rositano who have more than 27 years of experience working together on technology-related ventures. For more information, visit www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research Center at the University of Michigan Medical School; the two companies will work together to conduct a Phase 2a clinical trial for fibromyalgia that is the first Phase 2 study evaluating the efficacy of a psychedelic compound for the indication. In addition, Tryp also partnered with the University of Michigan and George Mashour, MD, PhD, to focus on the development of Tryp’s proprietary, psilocybin-based TRP-8803 drug product. TRYP is also working with Fluence on the design and implementation of innovative psychotherapy to be used with Tryp’s psilocybin-based drug compounds and Alcami to develop analytical methods and final formulations for Tryp’s drug products. Other corporate highlights for the company included the appointment of Robin Carhart-Harris, PhD, as chair of Tryp’s Scientific Advisory Board (“SAB”), as well as the addition of Daniel Clauw, MD, to the board. Financial numbers for the period ending May 31, 2021, include total assets of $6.1 million and net and comprehensive losses of $2.6 million. The company is also hosting a third-quarter virtual Investor Day, scheduled for July 29, 2021, at 9 a.m. PDT. Included on the event agenda will be a presentation by Tryp’s management team as well as a Q&A session. Tryp executives participating in the event include Greg McKee, chair and CEO; Luke Hayes, CFO; and Jim Gilligan, PhD, president and chief science officer. Interested individuals who are unable to attend can view a reply of the Investor Day on the company’s website for 30 days following the event.

To register for the event visit, https://ibn.fm/GSUs8

To view the full press release, visit https://ibn.fm/GFHrR H at

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and eating disorder indications. The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has received approval for its common shares to trade on the NYSE American LLC stock exchange. According to the announcement, the company anticipates that trading to begin on or about Aug. 5, 2021; the company will trade on the exchange using the symbol CYBN. The company will continue to list its common shares in Canada on the NEO Exchange under the symbol CYBN and on the Frankfurt Stock Exchange under the symbol R7E1. Shareholders are encouraged to check their accounts to make sure that change in exchange and symbol is made. “We are all delighted to receive this approval from the NYSE American and are thankful to our wonderful team and loyal investor base who have followed us on this journey so far,” said Cybin CEO Doug Drysdale in the press release. “As the first psychedelic biotech company that will now trade on this esteemed exchange in the U.S., we will commit resources to reach the broadest investor audience with our mission and will continue to accelerate our efforts to position Cybin as a leader in the sector.”

To view the full press release, visit https://ibn.fm/oAuhL

About Cybin Inc.

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About QualityStocksNewsBreaks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://ibn.fm/wO76R).

The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the bladder wall. Yet, it is almost impossible to detect and resect cancerous cells that lay flat against the bladder, leaving some cells behind and causing a higher risk of recurrence. Approximately 50% of patients who have had a cystoscopy to remove NMIBC see their cancer return. Right now, approximately 724,000 people are living in fear that their bladder cancer will come back (https://ibn.fm/Ker0P).

Blue Light Cystoscopy (“BLC”), used with and FDA approved imaging agent that fluoresces the cancer cells, was introduced in 2010. Although proven to be more effective in identifying cancerous cells and reducing recurrence, blue light is still only used in approximately 10% of bladder cancer procedures due to training, cost and ease-of-use issues.

To address these issues, Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. This patented technology allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. The i/Blue System will attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at a significant cost savings.

Imagin Medical’s technology has entered the manufacturing stage with the company’s partner, Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022.

With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder cancer visualization by radically changing how cystoscopies are performed and ultimately helping improve patients’ lives and long-term outlook. Imagin Medical’s target is estimated to be a $400M portion of the global endoscopy market valued at $25.59 billion in 2019 and is expected to grow at a CAGR of 6.6 percent to reach a total estimated value of $35.23 billion by 2024 (https://ibn.fm/5jNuO).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability

Lexaria Bioscience is a drug delivery technology developer advancing its IP for transforming existing consumer products and medications that may improve their availability and bioavailability
The analysis of Lexaria’s DehydraTECH(TM) shows it did not create unwanted new molecular entities during the transformation process, did not inhibit the drugs’ expected antiviral functions and did increase absorption
The DehydraTECH testing has been in conjunction with drugs used to treat SARS-CoV-2/COVID-19, HIV/AIDS and hepatitis, although the company envisions its technology becoming responsive to a much wider array of viral illnesses
The company envisions building on its recent successes with larger studies of the DehydraTECH process in animals infected with viruses such as SARS-CoV-2/COVID-19 or HIV/AIDS and hopes to eventually form partnerships with established pharmaceutical giants

Oral drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX)provided investors an update July 22 on the success of its efforts to advance its proprietary technology toward scalable commercial use for improving the treatment of select viral illnesses.

Lexaria has met three primary objectives in its investigation of antiviral drug conversion process outcomes as the antiviral drugs are processed with Lexaria’s patented DehydraTECH, according to the company’s news release (https://ibn.fm/H4wBZ).

Lexaria aims to make drugs more bioavailable through DehydraTECH conversion without impairing the drugs’ essential functions. Many antiviral drugs currently available experience a decrease in bioavailability when taken orally because of poor intestinal uptake and/or significant liver biotransformation within the patients’ bodies — the company cites the anti-inflammatory drug colchicine, which has a bioavailability of about 45 percent and a narrow margin between what is regarded as safe and toxic dosing.

Lexaria’s three primary objectives in testing DehydraTECH’s processing of colchicine and four other anti-inflammatories — darunavir, ebastine, efavirenz and remdesivir — were to determine if DehydraTECH processing would demonstrate evidence of increasing absorption through oral delivery, evidence that the drug compounds would continue to inhibit viruses as expected in mammalian cells, and evidence that the processing would not lead to the creation of new molecular entities (“NMEs”) requiring new regulatory approvals.

The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVD-19, HIV/AIDS or other infectious disease-causing viruses, according to the company, with the ultimate aim of forming partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics.

The five drugs being analyzed in conjunction with DehydraTECH processing are representative of protease inhibitors (“PIs”), reverse transcriptase inhibitors (“RTIs”) and a tubulin polymerization and microtubule inhibitor (“TPMI”) used to treat HIV, hepatitis C, hepatitis B, COVID-19 infections and cancers. Lexaria hopes to apply its discoveries to pharmaceuticals that fight other virus-triggered diseases such as shingles, influenza and viral forms of gastroenteritis, hepatitis, meningitis, and pneumonia.

The company’s news release cites statistics noting that 37.7 million people are currently known to be infected with HIV and 36.3 million people have died from HIV/AIDS since the beginning of the epidemic, between 290,000 and 650,000 people die every year from virus-driven seasonal influenza, and over 189 million people have been infected by SARS-CoV-2 in the current global epidemic with more than 4 million of them killed by the illness.

Vaccines have helped reduce the incidence and mortality of these viral illnesses, but effective oral delivery has the potential to increase the availability of medications where vaccines cannot be widely administered. Additionally, in each of the antiviral drug classes currently being tested, the outcomes in animals have demonstrated up to a three-fold increase in bioavailability to the bloodstream over established methods, which may ultimately prove a means of reducing the costs of administration.

“We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report (https://ibn.fm/OTtde). “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology,” Bunka stated.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocks Small-Cap and Micro-Cap Blogs

Thursday, July 29, 2021

QualityStocksNewsBreaks –Splash Beverage Group Inc. (NYSE American: SBEV) CEO Featured in SmallCapVoice.com Interview

QualityStocksNewsBreaks – PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) CEO Featured in M.A.D. Casters Interview

QualityStocksNewsBreaks – InnerScope Hearing Technologies Inc. (INND) Completes Financial Filing Requirements, Upgraded by OTC Markets

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

QualityStocksNewsBreaks – BAND Royalty Looking to Expand Royalty Library

QualityStocksNewsBreaks – Emaginos Inc.’s Scalable Solution Designed to Produce Profoundly Better Results for Existing Funds

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Study Results Indicating DehydraTECH-CBD Lowers Blood Pressure

QualityStocksNewsBreaks – Why Accure Acne Inc. Is ‘One to Watch’

QualityStocksNewsBreaks – Sustainable Green Team Ltd. (SGTM) Is an Industry Powerhouse

QualityStocksNewsBreaks – reAlpha CEO Authors Forbes Article Discussing Tech’s Disruption in the Real Estate Space

QualityStocksNewsBreaks – Hero Technologies Inc. (HENC) Eyes Strategic Business Plan Toward Vertical Integration

QualityStocksNewsBreaks – Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Begins Trading on NASDAQ under KAVL Ticker

QualityStocksNewsBreaks – AmpliTech Group Inc. (NASDAQ: AMPG) Featured in Stock2Me Podcast, Secures $0.5M in Follow-On Orders

QualityStocksNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Enters Strategic Alliance Focused on Recovery of Isotopes Needed for Emerging Cancer Therapeutics

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Announces LOI, Enters Promising Australian Medical Cannabis and OTC CBD Space

QualityStocksNewsBreaks – Friendable Inc. (FDBL) Featured in SmallCapVoice.com Interview

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Receives Listing Approval from NYSE American

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability

QualityStocks Links

Blog Archive

About Me